Geron Corp (GERN) Stock Price, Quote & News

Company Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractor...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 473 7700

Website: www.geron.com

Address:

919 East Hillsdale Boulevard, Suite 250, Foster City, United States

stefano62 May. 13 at 7:38 AM

$GERN did anybody join the web cast of the conference? If Is the case can summarize?

2 · Reply

Twillery May. 13 at 3:46 AM

$GERN Would somebody more knowledgeable than I please reply: Geron filed a $150 million ATM a few months ago to raise capital. Is the high-volume trading these past few days -- 30 million -- linked to the ATM? Has Geron starting selling shares in increments to raise at least part of the $150 million? Will we find out about a dilution during the next earnings report? Or does Geron have to disclose the implementation now, if it's started? Or am I thoroughly wrong in assuming a connection between the super high volume and the ATM?

2 · Reply

BubblesMcGee123 May. 13 at 1:33 AM

$GERN AI: On Geron's IMproveMF: A combination trial with imetelstat (Rytelo) and ruxolitinib (Jakafi), in phase 1b: "Why this trial is a "Secret Weapon" "While everyone is focused on the IMpactMF Phase 3 trial (the "stop or go" decision for the company), the IMproveMF Phase 1 is actually the one that could double the addressable market. IMpactMF looks at patients who have failed existing drugs. IMproveMF (this Phase 1 combo trial) is aiming for front-line use—meaning patients would take Rytelo and Jakafi together right from the start."

0 · Reply

Huntlardo May. 12 at 11:58 PM

$GERN sounds like any potential big pharma that wants to partner is gonna have to pay up big time, they are noting many different options to commercialize outside of the US to keep more percentage of ownership in house

0 · Reply

ZoeyTanner May. 12 at 10:27 PM

$GERN Disappointment, nothing new here. But look at SLS, see how to value your clinical trial. Leadership team there is soaring.

1 · Reply

Huntlardo May. 12 at 8:39 PM

$GERN the conference call doesnt start till 7:35 eastern its 4:35 PDT

0 · Reply

Radmanx May. 12 at 7:45 PM

$GERN Most of us that have been here for a while know that this volume is unusual. Very excited to see this pop soon!

0 · Reply

vonryan May. 12 at 7:02 PM

$GERN Surprise GERN is not getting greater love of interests and investment buying. Some day this stock will explode.

1 · Reply

Merlintrader May. 12 at 6:24 PM

$GERN Geron Q1 2026: RYTELO Growth Improves, But IMpactMF Still Defines the Bigger 2026 Setup https://www.merlintrader.com/geron-corporation-stock-hub/

0 · Reply

GangsterX May. 12 at 6:12 PM

$TCRX $GERN $PMVP 3 biggies bet and still holding

0 · Reply

Geron Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T19:13:58.000Z - 17 hours ago

Geron to present RWE study of RYTELO at EHA Congress

May 12, 2026, 9:31 AM EDT - 23 hours ago

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

2026-05-07T07:14:27.000Z - 6 days ago

Geron reports Q1 EPS (1c), consensus (2c)

May 6, 2026, 8:00 AM EDT - 7 days ago

Geron Earnings Call Transcript: Q1 2026

May 6, 2026, 7:00 AM EDT - 7 days ago

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 5, 2026, 8:00 AM EDT - 8 days ago

Geron Plans to Present at Upcoming Investor Conferences

Apr 22, 2026, 7:00 AM EDT - 21 days ago

Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

Apr 20, 2026, 4:05 PM EDT - 22 days ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 14, 2026, 4:05 PM EDT - 4 weeks ago

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 13, 2026, 11:00 AM EDT - 4 weeks ago

Geron Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-13T12:39:00.000Z - 4 weeks ago

Geron appoints Timothy Williams as chief legal officer

VNDA

Apr 13, 2026, 8:00 AM EDT - 4 weeks ago

Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary

Apr 6, 2026, 8:00 AM EDT - 5 weeks ago

Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 26, 2026, 8:00 AM EDT - 6 weeks ago

Geron Announces Appointment of New Members to its Board of Directors

Mar 10, 2026, 10:30 AM EDT - 2 months ago

Geron Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 2, 2026, 1:10 PM EST - 2 months ago

Geron Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T12:56:39.000Z - 2 months ago

Geron files automatic mixed securities shelf

Feb 25, 2026, 8:00 AM EST - 2 months ago

Geron Earnings Call Transcript: Q4 2025

2026-02-25T12:07:00.000Z - 2 months ago

Geron reports Q4 EPS (5c), consensus (4c)

2026-02-25T12:06:24.000Z - 2 months ago

Geron sees FY26 Rytelo revenue $220M-$240M

Feb 25, 2026, 7:00 AM EST - 2 months ago

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 11, 2026, 7:27 AM EST - 3 months ago

Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

2026-01-29T14:30:18.000Z - 3 months ago

Geron price target lowered to $3 from $4 at TD Cowen

2026-01-12T13:15:59.000Z - 4 months ago

Geron sees FY26 RYTELO product revenue $220M-$240M

Jan 12, 2026, 8:00 AM EST - 4 months ago

Geron Corporation Provides 2026 Financial Guidance

2025-12-11T13:05:32.000Z - 5 months ago

Geron announces restructuring plan, one-third workforce reduction

Dec 11, 2025, 8:00 AM EST - 5 months ago

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

2025-12-08T13:30:45.000Z - 5 months ago

Geron announces new data presented at ASH 2025

Dec 8, 2025, 8:02 AM EST - 5 months ago

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Dec 2, 2025, 11:15 AM EST - 5 months ago

Geron Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-11-14T14:40:23.000Z - 6 months ago

Unusually active option classes on open November 14th

EU GLNG SNDK SSRM TZA XPEV

Nov 11, 2025, 10:40 AM EST - 6 months ago

Geron Transcript: Stifel 2025 Healthcare Conference

Nov 5, 2025, 8:00 AM EST - 6 months ago

Geron Earnings Call Transcript: Q3 2025

2025-11-05T12:37:00.000Z - 6 months ago

Geron reports Q3 EPS (3c), consensus (4c)

2025-11-05T12:36:29.000Z - 6 months ago

Geron sees FY25 operating expenses $250M-$260M

Nov 5, 2025, 7:00 AM EST - 6 months ago

Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 4, 2025, 8:00 AM EST - 6 months ago

Geron Corporation to Present at Upcoming Investor Conferences

Nov 3, 2025, 9:05 AM EST - 6 months ago

Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

2025-10-13T20:40:09.000Z - 7 months ago

Geron COO Andrew Grethlein, CCO Jim Ziegler to depart

Oct 13, 2025, 4:34 PM EDT - 7 months ago

Geron Corporation Announces Executive Leadership Transitions and Appointments

Aug 27, 2025, 4:05 PM EDT - 9 months ago

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 14, 2025, 5:23 PM EDT - 9 months ago

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

2025-08-06T13:21:02.000Z - 9 months ago

Geron appoints Harout Semerjian as CEO

2025-08-06T12:12:10.000Z - 10 months ago

Geron reports Q2 EPS (2c), consensus (3c)

Aug 6, 2025, 8:00 AM EDT - 10 months ago

Geron Earnings Call Transcript: Q2 2025

Aug 6, 2025, 7:01 AM EDT - 10 months ago

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Geron Appoints Harout Semerjian as President and Chief Executive Officer

Jul 28, 2025, 8:00 AM EDT - 10 months ago

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

2025-07-10T09:00:26.000Z - 10 months ago

Geron resumed with a Sell at Goldman Sachs

May 28, 2025, 8:30 AM EDT - 1 year ago

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

2025-05-13T12:05:26.000Z - 1 year ago

GERN Lawsuit Alert! Class Action Lawsuit Against Geron Corporation

2025-05-08T13:02:54.000Z - 1 year ago

Geron price target lowered to $6 from $7 at Wedbush

May 7, 2025, 8:00 AM EDT - 1 year ago

Geron Earnings Call Transcript: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 18, 2025, 4:30 PM EDT - 1 year ago

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

stefano62 May. 13 at 7:38 AM

$GERN did anybody join the web cast of the conference? If Is the case can summarize?

2 · Reply

Twillery May. 13 at 3:46 AM

2 · Reply

BubblesMcGee123 May. 13 at 1:33 AM

0 · Reply

Huntlardo May. 12 at 11:58 PM

0 · Reply

ZoeyTanner May. 12 at 10:27 PM

$GERN Disappointment, nothing new here. But look at SLS, see how to value your clinical trial. Leadership team there is soaring.

1 · Reply

Huntlardo May. 12 at 8:39 PM

$GERN the conference call doesnt start till 7:35 eastern its 4:35 PDT

0 · Reply

Radmanx May. 12 at 7:45 PM

$GERN Most of us that have been here for a while know that this volume is unusual. Very excited to see this pop soon!

0 · Reply

vonryan May. 12 at 7:02 PM

$GERN Surprise GERN is not getting greater love of interests and investment buying. Some day this stock will explode.

1 · Reply

Merlintrader May. 12 at 6:24 PM

$GERN Geron Q1 2026: RYTELO Growth Improves, But IMpactMF Still Defines the Bigger 2026 Setup https://www.merlintrader.com/geron-corporation-stock-hub/

0 · Reply

GangsterX May. 12 at 6:12 PM

$TCRX $GERN $PMVP 3 biggies bet and still holding

0 · Reply

Huntlardo May. 12 at 5:00 PM

$GERN question for those whom maybe more knowledgable. why do the options chains not offer a 2028 leap contract? with all these events building up for 2h of 2026 and the only dated long option being january 2027 calls. does the market just not have interest in anything longer then that? im reading into this as the market is really expecting some fireworks to happen this year. interim results lead to halt due efficacy kind of fire works…

2 · Reply

SNOB_ORDER May. 12 at 4:47 PM

$GERN new US patent (04/30/26) 1. US20260115223 - METHODS OF TREATING MYELODYSPLASTIC SYNDROME https://patentscope.wipo.int/search/en/detail.jsf?docId=US478180829&_cid=P10-MP2V26-96619-1

0 · Reply

SNOB_ORDER May. 12 at 4:32 PM

$GERN “This is the first real-world study evaluating imetelstat in lower-risk MDS, and we are encouraged that the efficacy, safety and tolerability observed were generally consistent with findings from the Phase 3 IMerge trial in a broader patient population with a trend towards more optimal management of cytopenias,” said Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron. “These findings add to the growing body of evidence supporting the use of imetelstat as a preferred treatment option following prior therapy for patients with lower-risk MDS and significant transfusion burden. We look forward to presenting data from the prospective portion of this study later this year.”

0 · Reply

vonryan May. 12 at 3:52 PM

$GERN First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 Geron Corporation Tue, May 12, 2026 at 9:31 AM EDT 11 min read

1 · Reply

Huntlardo May. 12 at 2:14 PM

$GERN does anyone else think them presenting all these presentations at EHA is a nod to them putting emphasis on the EU, as in hey guys we are expecting big progress in the Eu soon…..

0 · Reply

Caliente44 May. 12 at 2:02 PM

$GERN There are two additional readouts later 2026 . Improve MF trial giving Ryteko with Jakafi and the Imagine trial giving Ryteko with azacitidine. I believe the time is near ffor the drug to demonstrate it’s true potential

0 · Reply

DoctrBenway May. 12 at 1:40 PM

$GERN Uptake takes time. Stay long and the numbers continually become more compelling as hematologists (prone to inertia until something is proven compellingly better) change their practice in MDS/MF. Analogy: I knew Cologuard would have uptake and bought tons of $EXAS in the $4 range, I knew low risk patients would eschew a prep and procedure once the diagnostic follow-up was covered.

0 · Reply

DoctrBenway May. 12 at 1:33 PM

$GERN https://ir.geron.com/news-releases/news-release-details/first-real-world-evidence-study-rytelor-imetelstat-lower-risk

0 · Reply

Caliente44 May. 12 at 12:01 PM

$GERN My two cents : Accumulation will happen from now till readout for MF trial later this year. Anticipate positive news .. if a trial halt then of course big move up if continuation then of course cash and stock dilution becomes a concern but stock will be derisked and a buyout is more likely then than now

1 · Reply

Huntlardo May. 12 at 10:24 AM

$GERN

0 · Reply

trex5280 May. 12 at 2:19 AM

$GERN Accumulation and Distribution: Significant volume spikes without corresponding price movement often indicate "smart money" accumulation or distribution. In an uptrend, this can signal that buyers are absorbing supply, potentially leading to a sharp price increase once selling pressure is exhausted.

1 · Reply

meistermell May. 12 at 12:26 AM

$GERN volume precedes price. This is too cheap here

0 · Reply

Market Cap	891.71M
Revenue (ttm)	183.88M
Net Income (ttm)	-83.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-45.41%
Debt to Equity Ratio	0.52

Volume	26,731,000
Avg Vol	18,473,006
Day's Range	N/A - N/A
Shares Out	641.52M
Stochastic %K	6%
Beta	0.68
Analysts	Sell
Price Target	$3.40